| 2024 | 2023 | 2022 | |||
|---|---|---|---|---|---|
| Financial Performance (Baht ‘000) | |||||
| Total current assets | 16,731,530 | 15,684,977 | 11,418,777 | ||
| Total assets | 32,653,045 | 29,212,105 | 24,258,811 | ||
| Trade receivables | 3,820,961 | 4,264,339 | 2,636,905 | ||
| Inventories | 355,939 | 362,256 | 325,739 | ||
| Total current liabilities | 3,826,729 | 4,184,351 | 3,414,969 | ||
| Total liabilities | 4,852,114 | 5,114,316 | 4,253,493 | ||
| Trade payables | 1,060,738 | 995,238 | 972,107 | ||
| Total shareholders’ equity | 27,800,931 | 24,097,789 | 20,005,318 | ||
| Total revenues | 25,862,450 | 25,574,976 | 20,907,533 | ||
| Total expenses | 16,697,114 | 17,074,978 | 14,900,475 | ||
| Share of income(loss) from investments in joint venture and associated companies | (427) | (897) | (510) | ||
| Profit before finance cost and income tax expenses | 9,444,382 | 8,640,049 | 6,052,502 | ||
| Net profit excluding extraordinary Items | 7,774,726 | 7,006,451 | 4,938,222 | ||
| Net profit for the year | 7,774,726 | 7,006,451 | 4,938,222 | ||
| Basic earnings per share | 9.78 | 8.81 | 6.21 | ||
| Earnings per share - fully diluted | 8.96 | 8.08 | 5.69 | ||
| Book value per share | 34.97 | 30.32 | 25.17 | ||
| Book value per share - fully diluted | 32.05 | 27.78 | 23.06 | ||
| Dividend per share | 5.00 | 4.50 | 3.50 | ||
| Net cash flows from operating activities | 8,671,234 | 7,094,365 | 6,212,622 | ||
| Net cash flows used in investing activities | (4,984,873) | (2,428,594) | (3,222,521) | ||
| Net cash flows used in financing activities | (4,224,199) | (3,050,793) | (2,656,112) | ||
| Financial Ratios | |||||
| Gross profit margin (%) | 53.8 | 51.6 | 49.3 | ||
| EBIT Margin (%) | 35.4 | 33.2 | 28.7 | ||
| EBITDA margin (%) | 39.6 | 37.5 | 34.1 | ||
| Net profit margin excluding extraordinary items (%) | 30.1 | 27.4 | 23.6 | ||
| Net profit margin (%) | 30.1 | 27.4 | 23.6 | ||
| Growth on revenues from hospital operations (%) | 1.3 | 22.5 | 66.4 | ||
| Growth on net profit excluding extraordinary Items (%) | 11.0 | 41.9 | 288.2 | ||
| Growth on net profit for the year (%) | 11.0 | 41.9 | 306.2 | ||
| Return on equity excluding extraordinary Items (%) | 30.0 | 31.8 | 26.2 | ||
| Return on equity (%) | 30.0 | 31.8 | 26.3 | ||
| Return on assets excluding extraordinary Items (%) | 25.1 | 26.2 | 21.9 | ||
| Return on assets (%) | 25.1 | 26.2 | 21.9 | ||
| Liabilities to equity (x) | 0.2 | 0.2 | 0.2 | ||
| Debt to equity (x) | 0.0 | 0.0 | 0.0 | ||
| Net debt to equity (x) | (0.1) | (0.2) | (0.1) | ||
| Interest coverage ratio (x) | 1,228.9 | 4,008.7 | 2,008.4 | ||
| IBD/EBITDA (x) | 0.0 | 0.0 | 0.0 | ||
| DSCR (x) | 955 | 892 | 662 | ||
| IBD1Year/IBD (%) | 30.6 | 30.8 | 30.8 | ||
| Liquidity ratio (x) | 4.4 | 3.7 | 3.3 | ||
| Cash Cycle (days) | 42.2 | 36.1 | 24.0 | ||
| Average collection Period (days) | 59.8 | 52.4 | 39.4 | ||
| Average inventory Period (days) | 10.9 | 10.1 | 11.2 | ||
| Average payable Period (days) | 28.5 | 26.4 | 26.7 | ||
Remarks: IBD means interest-bearing debt, which excludes liabilities under finance lease agreements.
